Protara Therapeutics (TARA) reported second-quarter 2026 financial results and provided updates across its clinical-stage pipeline. The company incurred a net loss of $21.7 million, or $0.36 per share, compared with a net loss of $15.0 million, or $0.35 per share, in the prior-year period.
Protara said unrestricted cash, cash equivalents and marketable debt securities totaled $161.9 million as of June 30, 2026, which it expects will fund planned operations and milestones into 2028.
- Research and development expenses rose to $17.0 million from $10.8 million a year earlier.
- General and administrative expenses increased to $6.4 million from $5.8 million in the prior-year period.
- The company expects to complete enrollment of the BCG-Unresponsive cohort in the ADVANCED-2 trial in the fourth quarter of 2026.
- Protara is redesigning ADVANCED-3 as a multi-cohort, open-label exploratory trial in high-grade, high-risk NMIBC patient groups.
- The company expects to complete enrollment of STARBORN-1 in lymphatic malformations in the fourth quarter of 2026 and submit a BLA for TARA-002 in the second half of 2027.
- Interim results from the THRIVE-3 registrational trial of IV Choline Chloride are expected in the fourth quarter of 2026.
$TARA Insider Trading Activity
$TARA insiders have traded $TARA stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TARA stock by insiders over the last 6 months:
- JESSE SHEFFERMAN (CEO and President) sold 215,687 shares for an estimated $882,159
- JACQUELINE ZUMMO (Chief R&D Officer) sold 1,134 shares for an estimated $6,123
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$TARA Hedge Fund Activity
We have seen 69 institutional investors add shares of $TARA stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MILLENNIUM MANAGEMENT LLC added 2,077,906 shares (+275.8%) to their portfolio in Q1 2026, for an estimated $10,825,890
- AIGH CAPITAL MANAGEMENT LLC removed 1,622,733 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $6,198,840
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 1,259,427 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,561,614
- POINT72 ASSET MANAGEMENT, L.P. added 1,124,607 shares (+4001.2%) to their portfolio in Q1 2026, for an estimated $5,859,202
- PATIENT SQUARE CAPITAL LP added 1,030,846 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,370,707
- CATALIO CAPITAL MANAGEMENT, LP removed 866,230 shares (-59.9%) from their portfolio in Q1 2026, for an estimated $4,513,058
- J. GOLDMAN & CO LP added 856,247 shares (+inf%) to their portfolio in Q1 2026, for an estimated $4,461,046
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
